Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level
Recruiting now · Phase 3
Conditions studied: Multiple Myeloma (MM), Plasma Cell Leukemia (PCL)
In brief
iFIT is a trial for newly diagnosed transplant-ineligible patients with the bone marrow cancer myeloma. These patients are generally older and have a lower level of fitness than others. Patients can take part if their doctor would otherwise recommend the standard NHS treatment daratumumab, lenalidomide and dexamethasone (DRd). After six months of DRd, the subsequent treatment a patient receives in iFIT is based on two factors: the patient's fitness level and treatment response. The trial compares different treatment strategies to determine whether outcomes can be improved for specific patient groups.
Key facts
- Study ID
- NCT07649525
- Run by
- University of Leeds
- People needed
- 1226
- Starts
- 2026-07-01
- Expected to finish
- 2037-06-01
- Last updated by the study team
- 2026-07-15
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- The Clatterbridge Cancer Centre - Liverpool — Liverpool, United Kingdom (enrolling)
- Bristol Haematology and Oncology Centre — Bristol, United Kingdom
- Eastbourne District General Hospital — Eastbourne, United Kingdom
- St James University Hospital — Leeds, United Kingdom
- The Royal Marsden Hospital — London, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.